Introduction
============

Obesity increases the risk of type 2 diabetes, cardiovascular disease and other chronic diseases.^[@bib1],\ [@bib2]^ Weight reduction is associated with significant improvements in blood pressure, serum cholesterol levels and glycaemic control.^[@bib3]^ Achieving negative energy balance is an important factor in determining the magnitude and rate of weight loss.^[@bib4]^ Calorie-restricted diets, ideally combined with exercise and behaviour modification, are considered to be the initial treatment strategy for overweight and obese individuals. Low-calorie diets at a level of 1000--1200 kcal per day for most overweight women and 1200--1600 kcal per day for most overweight men are often recommended for weight loss.^[@bib5]^ With low-calorie diets, maintaining satiety is critical, as perceived hunger has been shown to be a significant predictor of failure to lose weight.^[@bib6]^ After weight loss is achieved, appetite often increases leading to refractory weight gain.^[@bib7]^ Identifying factors that suppress appetite is important for successful weight loss and maintenance.

Increased fibre intake has been associated with reduced energy intake and increased satiety, and may be an important factor in obesity management.^[@bib8]^ A meta-analysis of 22 studies concluded that consumption of 14 g of fibre per day resulted in a 10% decrease in energy intake and a 1.9-kg weight loss over 3.8 months.^[@bib9]^ Viscous soluble fibres, in particular, appear to increase satiety^[@bib10],\ [@bib11],\ [@bib12],\ [@bib13],\ [@bib14]^ and promote adherence to calorie-reduced diets.^[@bib15],\ [@bib16]^ Accordingly, consuming substantial quantities of viscous dietary fibre may provide significant therapeutic benefits under conditions of reduced energy intake. However, as the benefit of these fibres is related to viscosity,^[@bib17]^ their acceptance is often hampered by issues of palatability.^[@bib18]^

Recently, PolyGlycopleX (PGX), a novel, highly viscous non-starch polysaccharide complex has been developed for human consumption. This soluble dietary fibre displays delayed viscosity for 15--30 min after ingestion, thus, allowing for a more palatable and easy-to-use functional fibre. In a recent randomised, placebo-controlled trial, PGX was shown to diminish hunger and reduce *ad libitum* food consumption compared with less viscous fibres (cellulose and glucomannan) given in meal-replacement drinks.^[@bib19]^ The objective of this study was to investigate the effect of supplementing a three-day low-calorie diet with PGX on subjective ratings of appetite compared with a placebo in overweight and obese women.

Materials and methods
=====================

Subjects
--------

Subjects were recruited through local newspaper advertisements. Women with a body mass index between 25 and 34.9 kg m^−2^ and between 20 and 50 years of age were eligible to participate. Exclusion criteria included: pregnancy or lactation, smoking, consumption of more than two alcoholic drinks daily or nine alcoholic drinks weekly, recent participation in a calorie-reduced diet, the presence of chronic diseases, past history of gastrointestinal surgery, a change in body weight of more than 3 kg during the last 3 months, hypersensitivity to the study foods, taking medication or natural health products, which may affect gastrointestinal motility hunger or appetite. Furthermore excluded were those who scored 9 or more on the restraint scale; 27 or above for uncontrolled eating, or 18 or greater for emotional eating on the Three-Factor Eating Questionnaire-R18V2, validated for Canadian and US obese and non-obese individuals.^[@bib20]^ As lower palatability of foods may diminish the sensation of hunger and desire to eat,^[@bib21]^ a Food Preference Questionnaire was used to ensure that all the participants expressed acceptance of the foods included in the study. Those scoring less than 3 for more than 50% of the food items were excluded from the study. The University of British Columbia Research Ethics Committee approved the study and all subjects gave informed consent to participate.

Study supplements
-----------------

PGX (α\--glucurono-α\--manno-β\--manno-β\--gluco), (α\--gulurono-β- mannurono), β\--gluco-β\--mannan (Inovobiologic, Calgary, Alberta, Canada) is a novel functional fibre complex^[@bib22],\ [@bib23]^ manufactured by a proprietary process from three fibres (konjac (glucomannan), sodium alginate and xanthan gum) to form a highly viscous polysaccharide (higher viscosity than any currently known individual polysaccharide or fibre blend) with high water-holding and gel-forming properties. PGX has been shown to be safe and well tolerated in rodents^[@bib24]^ and in humans.^[@bib25]^ Genotoxicity studies of PGX have shown no mutagenic effects using bacterial reverse mutation and mouse micronucleus assays.^[@bib26]^ PGX is 87.4% dietary fibre, of which 81.8% is soluble. It can be sprinkled on food before consumption or taken with soup or beverage before meals. Rice flour was used as a placebo and has been used in other clinical trials for its white colour, neutral taste and hypoallergenicity.^[@bib27],\ [@bib28]^ PGX and rice flour both consist of approximately similar carbohydrate content with carbohydrate in PGX being dietary fibre and in rice flour being starch. Boiling or other forms of moist heat processing is required for rice flour to be effectively digested. Without cooking, only about 1% of the starch in raw rice flour is digested.^[@bib29]^ Therefore, the carbohydrate in uncooked rice flour is essentially dietary fibre resulting in rice flour\'s caloric value that closely approximates PGX. Both study supplements were packaged with clear plastic scoops in white plastic containers containing 100 g and were indistinguishable from each other.

Study design/protocol
---------------------

The study was a prospective, randomised, double-blind, placebo-controlled crossover trial. The study had two experimental phases with a 3-week washout. Test periods were on the same days of the week (Tuesday--Thursday) and were conducted during the follicular phase (days 4--10) of the women\'s menstrual cycle to minimise hormonal influences on eating/feeding behaviour and appetite.^[@bib30]^ On Monday of the test week, subjects attended the clinic where their bodyweight was measured, study food was provided and they were randomised to either the test or placebo supplement. During the test period, subjects consumed the breakfasts, lunches and dinners provided immediately after the food was sprinkled with 5 g of supplement or placebo. Participants completed visual analogue scales (VAS) questionnaires at specified times (see below). To avoid a second meal effect and to minimise differences in glycogen stores, the night before consumption of the 3-day low-calorie diet, all subjects consumed the same evening meal. In addition, participants were instructed not to consume alcohol or engage in vigorous physical activity 48 h before consuming the low-calorie diet. On Friday, subjects returned to the clinic to have their compliance assessed, documents reviewed and to have any adverse effects recorded. To assess compliance, subjects kept a log of daily food and study product consumed and returned the product containers for weighing.

Low-calorie diet
----------------

A three-day structured low-calorie diet of 1000 kcal per day was provided with the intention that caloric restriction would accentuate feelings of hunger. The low-calorie diet was designed to provide participants with 65% of energy as carbohydrate, 10% protein, and 15% fat ([Appendix 1](#app1){ref-type="app"}). Commercially available frozen dinner entrees (President\'s Choice Blue Menu, Loblaw, Ontario, Canada) were provided to participants to standardise caloric intake and macronutrient composition.

Subjective appetite measures
----------------------------

Rating subjective appetite using VAS is a valid and reliable measure of appetite under both experimental and free-living conditions, especially when using a within-subject design, as used in the current study.^[@bib31],\ [@bib32]^ VAS ratings were made on a 100-mm scale with words anchored at either end in the following order: first, 'How strong is your desire to eat?\' (Very strong---Very weak); second, 'How hungry do you feel?\' (Not hungry at all---Very hungry); third, 'How full do you feel?\' (Very full---Not at all full); and fourth, 'How much food do you think you could eat?\' (A large amount--Nothing at all), which assesses prospective consumption. The palatability of the meals was also evaluated after meals by a fifth question asking 'How would you rate the overall palatability of the food? (Unpalatable---Very palatable). The times of rating were the same every day for both phases; however, to work with participants at various schedules, different start times in the morning were available. VAS were completed before (e.g., 0755 h) and after breakfast (e.g., 0830 h), in between the morning meals (e.g., 1030 h), before (e.g., 1225 h) and after (e.g.,1300 h) lunch, in between meals in the afternoon (e.g., 1500 h, 1700 h), before (e.g., 1725 h) and after (e.g., 1800 h) dinner and in the evening (e.g., 2000 h). Participants were provided with programmable alert wrist watches (CADEX Medication reminder watch, e-pill, LLC., Wellesley, MA, USA) to remind them when to eat and when to complete the questionnaires. Participants were allowed 20 min to consume the food, supplement and 500 ml of water, and were allowed to consume an additional 500 ml of water between meals. Participants were instructed not to consume water 30 min before completing premeal VAS. All food and water consumed during Phase 1 was recorded and the same amount was provided for Phase 2.

Statistical analyses
--------------------

Changes in weight over each test period were tested for differences between treatment groups using the Wilcoxon rank sum test. For compliance, the *P*-values of differences between the two treatment groups within a single period were calculated from two-sample *t*-tests; the statistical test for the summary across both periods of data used a linear mixed model approach, which took into consideration that the same participants appeared once on each of the two treatments (due to the crossover design). For VAS score analyses, the area under the curve was analysed on the log scale to meet the distributional assumptions required for the statistical methods. The treatment effect was estimated from a linear mixed-effects model to take into consideration the crossover design of the study; the model was adjusted for phase, treatment, randomised sequence and a within-patient comparison was made to assess the treatment effect. With the different study days expected to give differences in results, the analysis was carried out by days 1, 2, 3 and on the mean of days 1--3. To analyse VAS scores by time point, a similar linear mixed model was used incorporating terms in the model for treatment, phase, randomised group and time point, and then contrasts used to compare the treatment groups at the different time points. Statistical testing of the adverse event rates by treatment (either overall rates, treatment-related rates or rates for specific types of adverse events) was performed using generalised estimating equations logistic regression models. To evaluate whether there was a carryover effect in the second period by the randomised sequences, a standard statistical approach by Jones *et al.*^[@bib33]^ was used to assess. For all statistical tests, the significance level was set at 0.05. All analyses were performed using SAS (Version 9.1.3, SAS Institute, Cary, NC, USA).

Results
=======

In total, 51 individuals were recruited for the study of which 45 were randomised ([Table 1](#tbl1){ref-type="table"}). After Phase 1, five discontinued from the study. The reasons for withdrawal were adverse events (*n*=2), dislike of the frozen meals offered (*n*=1) and personal reasons unrelated to the study (*n*=2). Overall, 40 participants completed the entire study; however, only 35 participants were included in the per-protocol analyses as 2 participants deviated from the protocol and 3 reported feeling sick, which might affect subjective appetite ratings. Compliance was high for both groups, with 107% and 97% for the rice flour and PGX groups, respectively. There was no carryover effect in the second period by the randomised sequences.

Weight loss was similar between groups over the two phases (PGX 1.3 kg versus placebo 1.4 kg; *P=*0.376). From the intent-to-treat analysis (*n*=40), the PGX treatment resulted in a significantly lower mean area under the curve on day 3 for prospective consumption (*P*=0.018) and a trend towards significance for hunger (*P*=0.059). After elimination of the protocol deviators (*n*=35), a similar pattern was seen with the differences between groups stronger with a mean percent change of prospective consumption at −14.7 (*P*=0.017) and hunger at −14.8 on day 3 (*P*=0.048, [Table 2](#tbl2){ref-type="table"}). There were no statistical differences in mean area under the curve for any of the scores for day 1 or 2, or the mean days 1--3, except for prospective consumption (*P*=0.026). The majority of differences in subjective ratings between the placebo and PGX groups at various time points were detected on day 3. PGX supplementation significantly reduced total appetite, desire to eat, hunger, prospective consumption, and it was associated with increased fullness at 2.5 h after lunch ([Figure 1](#fig1){ref-type="fig"}); reduced total appetite, desire to eat, hunger and prospective consumption at 4.5 h after lunch ([Figure 2](#fig2){ref-type="fig"}) and reduced total appetite, hunger and prospective consumption before dinner ([Figure 3](#fig3){ref-type="fig"}). Hunger was also reduced at 2.5 h after dinner (*P*\<0.05). For palatability, there was a statistically significant difference in mean palatability VAS scores by treatment for each day (*P*\<0.05), with PGX^-^supplemented meals scoring above 50 mm, but 5--10 mm below mean rice flour scores (data not shown).

Adverse events reported by both treatment groups are summarised in [Table 3](#tbl3){ref-type="table"}. There was no statistical difference between the two treatment groups in terms of the adverse events experience of the participants. Furthermore, the overall or treatment-related adverse events were similar for the two treatments.

Discussion
==========

This study demonstrates that adding 5 g of PGX to meals at the start of a low-calorie diet helps manage appetite by increasing satiety and decreasing prospective consumption (the amount one thinks one could eat). This effect was not statistically significant until day 3; however it resulted in reductions above 10% compared with the control, a magnitude which is considered to be of practical relevance.^[@bib32]^ With respect to time of day, PGX was found to exert its strongest effects in the afternoon and in the evening, reducing total appetite, hunger, desire to eat and prospective consumption. These results might be particularly helpful in managing obesity, given reports that food intake tends to be less in the morning and greater in the afternoon and highly evening in obese versus normal weight individuals.^[@bib34]^ One explanation for the effect seen with PGX on day 3 could be the increased fibre load. This particular test day had 7 g more dietary fibre and 9--10 g less protein than on day 1 or 2, resulting in a possible synergistic effect and interaction between the PGX and the dietary fibre content of the meals. Another possibility may be the cumulative effects of PGX over time with the potential for upregulation of gut-satiety hormone gene expression (such as proglucagon) via fermentation and production of short-chain fatty acids in the large bowel.^[@bib35]^

Soluble fibres that are fermentable by gut microbiota and produce significant quantities of short-chain fatty acids may contribute to appetite regulation by stimulating the release of gut-satiety hormones such as peptide YY (PYY) and glucagon like peptide-1.^[@bib36]^ In a study using Zucker diabetic rats, PGX consumption was associated with a significant increase in glucagon like peptide-1 levels.^[@bib37]^ In a 3-week human tolerance trial, supplementation of regular diets with 10 g of PGX per day was associated with higher fasting PYY levels than placebo control.^[@bib38]^ It has been reported that obese individuals have lower fasting and postprandial circulating PYY levels than lean individuals,^[@bib39],\ [@bib40]^ which may result in impaired satiety and may contribute to the development of obesity and may hinder weight loss efforts. To produce an equivalent stimulation of PYY sufficient to promote satiety, obese individuals need to consume a much greater caloric load than their lean counterparts.^[@bib39]^ An alternative to a greater caloric load could be a volumetric, lower energy dense load from supplementing a meal with PGX to augment PYY levels and stimulate satiety. Further investigation of a low-calorie diet supplemented with PGX on gut-satiety hormones is thus warranted.

Under conditions of fixed energy intake, such as a low-calorie diet, viscous soluble fibres may also alter the viscosity of gastrointestinal content resulting in multiple effects on satiety. A magnetic resonance imaging study by Marciani *et al.*^[@bib41]^ showed that a high-viscosity nutrient meal had the strongest additive effect in gastric distension and delayed gastric emptying compared with low-viscosity non-nutrient, low-viscosity nutrient and high-viscosity non-nutrient meals. Viscous soluble fibres also delay the absorption of nutrients by thickening the unstirred layer at the gut mucosal surface. This results in the transport of larger amounts of nutrients to the ileum and/or distributes nutrient absorption over a larger intestinal luminal surface area, leading to a more pronounced inhibitory feedback from the distal gut and activation of the ileal brake.^[@bib42]^ Other mediators of the ileal brake include the gut-satiety hormones PYY and glucagon like peptide-1 and vagal nerve stimulation.^[@bib43]^ The ileal brake is a distal to proximal negative feedback mechanism that inhibits gastric emptying, proximal gastrointestinal motility and secretion to control the transit of a meal through the gastrointestinal tract, which consequently optimises nutrient digestion and absorption.^[@bib44]^

As a highly viscous soluble fibre, PGX may cause a delay in gastric emptying and/or prolong the transport of nutrients down the gastrointestinal tract as demonstrated by previous research on its effects on the glycaemic index (GI). The GI is a property of carbohydrate-containing food that describes the rise of blood glucose occurring after a meal. High GI foods are classified as being rapidly digested and absorbed into the bloodstream, resulting in a sharp rise and in a steep decline of blood glucose after consumption, whereas low GI foods are broken down more slowly by a slower rate of digestion and absorption and releasing glucose more gradually into the bloodstream.^[@bib45]^ When 2.5--5 g of PGX was sprinkled on high and moderate GI foods, it was consistently shown to be highly effective in significantly reducing their glycaemic index.^[@bib45],\ [@bib46]^ Influencing the digestive rate of foods and their blood glucose response may have an important effect on the perception of satiety. Arumugam *et al.*^[@bib47]^ examined the effects of high-GI versus low-GI meals on subjective satiety in overweight and obese women. They found that the appetite score was 35% higher at 4 h after the high-glycaemic versus low glycaemic breakfast, and that at 3, 4 and 5 h after lunch, the appetite score was 30--44% higher in the high glycaemic condition.^[@bib47]^ Many other short-term studies (\<1 day) have also reported a significant relationship between the glycaemic response and satiety using foods with varying glycaemic indices.^[@bib48],\ [@bib49],\ [@bib50],\ [@bib51]^ In the present study, the frozen meals were chosen to represent the average Western diet with convenient, processed higher GI foods and as such the effect of PGX supplementation on the study foods\' glycaemic indices might be related to the 28%, 14%, 12% reduction of total appetite score at 2.5, 4.5, 5 h, respectively, after consuming the lunch on day 3. If however the study foods had a low GI, PGX may not have exerted as significant an effect on satiety.

This study was designed to alleviate some potentially confounding variables in appetite research. The timing of the test phases was scheduled according to participants\' menstrual cycle, given that previous research has linked changes in gastrointestinal function, appetite and energy intake to the follicular and luteal phases of menstruation.^[@bib30]^ The energy intake, macronutrient composition, water consumption and eating schedule for all the meals over the three-diet days were controlled, demonstrating the effect of PGX on homeostatic hunger (physiological). Although the effect of PGX on *ad libitum* food intake cannot be concluded, prior research has shown that subjective ratings of appetite appear to be good indicators of motivation to eat and are predictors of actual food intake.^[@bib31],\ [@bib52],\ [@bib53]^ However, it should also be mentioned that appetite ratings have not always been found to correlate with *ad libitum* food intake,^[@bib10]^ as many factors influence food intake, including sensory hedonics, external factors, cognitive issues, body weight, genes and so on.^[@bib54],\ [@bib55],\ [@bib56]^

To minimise the effect of palatability on appetite ratings, women who rated the palatability of the meals low were excluded. However, a significant difference in palatability between meals supplemented with PGX and rice flour was observed on all of the three-diet days. Previous research with PGX has not found any significant differences in palatability scores in comparisons with controls.^[@bib19],\ [@bib45]^ Study participants were advised to sprinkle PGX granules as they ate; however, the hot microwaved meals for lunch and dinner more than likely accelerated viscosity development, thereby affecting texture and palatability. This difference may be related more to texture than to any gastrointestinal discomforts experienced with PGX, as there was no statistical difference in adverse events reported between PGX and rice flour. Although palatability affects appetite,^[@bib57],\ [@bib58]^ this did not translate into significant differences in subjective appetite scores for days 1 and 2, suggesting that the difference observed on day 3 may have not been due to the palatability of the PGX^-^supplemented meal. When designing placebo-controlled trials with PGX, it is difficult to find a comparable inert substance and completely avoid any potentially confounding effect. Uncooked rice flour was found to closely approximate PGX in terms of flavour and texture, and it was thus judged to be a suitable placebo. However, the presence of resistant starches may have produced an increase in fermentation in the control group and dampened the difference in results between the two interventions.

As an initial investigation, this study was performed over 3 days because of the number of VAS questionnaires dispensed and strict adherence required for the food and meal schedule. It was conducted under free-living conditions so as to mimic people following a structured low-calorie diet in their regular lives. However, this inherently introduced some variability in the participants\' environment, occupational and non-occupational activities, which could have resulted in diurnal variations in appetite.^[@bib59]^ Furthermore, the diet during the two test phases was self-administered and even though compliance of the study supplements was high, the possibility of noncompliance with the prescribed diets could not be completely avoided.

In summary, this study indicates that the supplementation of highly viscous PGX to meals could be a useful weight management aid during a low-calorie diet to help lessen feelings of hunger and to moderate food portions. Weight relapse after consuming a low-calorie diet is a common outcome of obesity interventions. Therefore, long-term studies investigating the effects of PGX on subjective appetite and the maintenance of reduced body weight would be warranted. In addition, it would be useful to examine the effects of PGX on biomarkers such as glucagon like peptide-1, PYY and ghrelin to better understand some of the physiological influences of PGX on satiety. By virtue of its multiple physiological effects on the mechanisms of satiety, PGX may be an effective weight-management aid for low-calorie diets.
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The nutritional composition of the three-day low calorie diet

[Table A1](#tbl4){ref-type="table"}
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![Comparison of 2.5 h post breakfast, lunch and dinner mean hunger and prospective consumption scores of day 3 of the 1000-kcal calorie diet supplement with either 5 g of PGX or placebo at each meal. Values shown are mean±s.e. (*n*=35). ^\*^Significantly lower scores with PGX than with the placebo supplement (*P*\<0.05).](nutd201118f1){#fig1}
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![Comparison of predinner mean hunger and prospective consumption scores of day 3 of the 1000-kcal calorie diet supplement with either 5 g of PGX or placebo at each meal. Values shown are mean±s.e. (*n*=35). ^\*^Significantly lower scores with PGX than with the placebo supplement (*P*\<0.05).](nutd201118f3){#fig3}

###### Subject characteristics

                                                                   *Value (range)*
  ---------------------------------------------------------------- ------------------------
  Age (years)                                                      38.6±9.1 (20--50)
  Weight (kg)                                                      79.8±9.3 (59.4--107.8)
  Body mass index (kg m^−2^)                                       29.9±2.8 (25.0--34.8)
  Waist circumference (cm)                                         87.0±7.4 (73.3--106.0)
                                                                    
  *Three-factor eating questionnaire*[a](#t1-fn2){ref-type="fn"}   
   Cognitive                                                       7.3±3.1 (4.0--25.0)
   Uncontrolled eating                                             21.2±4.6 (5.0--27.0)
   Emotional eating                                                14.3±3.8 (7.0--24.0)

Values are mean±s.d.; *n*=45.

The Three-Factor Eating Questionnaire evaluates some aspects of eating behaviours such as cognitive restraint (i.e., the voluntary control of eating), the tendency to lose control of food intake when faced with external cues, mood changes or disruptive events (i.e., disinhibition) and susceptibility to feelings of hunger. In this study, the Three-Factor Eating-R18V2 questionnaire was used as a means to exclude those who have potentially disordered eating motivation and to assess motivation of the participants eligible for the study.^[@bib20]^

###### Daily and 3-day average comparison of subjective appetite measurements calculated as mean area under the curve in response to placebo or PGX for the per-protocol subject group

  *Score*                          *Day*          *Placebo*      *PGX*      *% Change*   P*-value*
  ------------------------- ------------------- ------------- ------------ ------------ -----------
  Prospective consumption            1           457.2±29.4    432.5±27.8      −5.4        0.358
                                     2           477.9±33.1    427.1±29.6     −10.6        0.079
                                     3            471±32.5     401.8±27.7     −14.7        0.017
                             Average days 1--3   468.6±28.9    420.2±25.9     −10.3        0.026
  Desire                             1           432.5±29.4    428.8±29.1      −0.9        0.894
                                     2           456.3 ±34.2   416.9±31.3      −8.6        0.273
                                     3            427.7±35     387.9±31.7      −9.3        0.280
                             Average days 1--3   438.6±29.7    410.8±27.8      −6.3        0.303
  Fullness                           1           598.3±40.3    591.6±39.9      −1.1        0.832
                                     2           584.5±50.7    574.5±49.8      −1.7        0.785
                                     3           614.1±47.2    632.3±48.6       3          0.592
                             Average days 1--3   598.8±43.8     599±43.9        0          0.996
  Hunger                             1           431.5±28.6    418.3±27.7      −3.1        0.651
                                     2           434.9±33.6    407.6±31.5      −6.3        0.429
                                     3           440.4±32.9     375.4±28      −14.8        0.048
                             Average days 1--3   435.6±28.4     400±26.1       −8.2        0.162
  Total appetite                     1           469.8±27.3    458.7±26.7      −2.4        0.675
                                     2           475.9±31.8    449.4±30.0      −5.6        0.390
                                     3           464.5±31.9    414.3±28.4     −10.8        0.106
                             Average days 1--3    470±27.9     440.4±26.2      −6.3        0.215

Abbreviation: PGX, PolyGlycopleX.

Note: *P*-value is from a linear mixed-model fit on log scale of area under curve and adjusting for potential sequence and period effects in addition to treatment (significance level *P*\<0.05).

Values shown are mean±s.e.; *n*=35.

###### Summary of the adverse events (AEs) by treatment allocation

  *Variable*                                                            *Placebo*      *PGX*      P*-value*
  ------------------------------------------------- ------------------ ------------ ------------ -----------
  Number of participants                                                    38           42            
  Participants reporting adverse events                                 13 (34.2%)   12 (28.6%)      0.7
  Total adverse events                                                      25           28            
  Participants reporting treatment-related events                       8 (21.1%)    11 (26.2%)     0.34
  Total treatment-related Events                                            19           24            
  Total adverse events (by severity)                Unknown severity        0            0             
                                                    Mild                    5            2             
                                                    Moderate                13           21            
                                                    Severe                  7            5             
  Total treatment-related events (by severity)      Unknown Severity        0            0             
                                                    Mild                    4            2             
                                                    Moderate                9            18            
                                                    Severe                  6            4             
  Participants reporting AEs by type of AE          Constipation         3 (7.9%)     1 (2.4%)      0.15
                                                    Diarrhea             0 (0.0%)     3 (7.1%)       NA
                                                    Bloating            4 (10.5%)     8 (19%)       0.07
                                                    Flatulence           0 (0.0%)     2 (4.8%)       NA
                                                    Headache            4 (10.5%)     1 (2.4%)      0.17
                                                    Cramping             3 (7.9%)     3 (7.1%)      0.59
                                                    Sick/unwell         4 (10.5%)     1 (2.4%)      0.08
                                                    Other                3 (7.9%)    7 (16.7%)      0.06

Abbreviation: PGX, PolyGlycopleX.

Parentheses denote the percentage from the total number of participants.

Some *P*-values were not possible to compute due to no events being reported under one of the treatment groups. These are noted as 'NA\' in the table.

######  

                                             *Quantity*    *Calories*   *Carbohydrate (g)*   *Fibre (g)*   *Protein (g)*   *Fat(g)*
  ------------------------------------------ ------------ ------------ -------------------- ------------- --------------- ----------
  *Day 1*                                                   **1004**         **156**            **7**         **55**        **16**
   Breakfast                                                  244               38                               8            5
    Blue Menu granola cereal                 0.5 cup          165               30                3              3            2
     Milk 2%                                 150 ml            77               7                                5            3
    Tea or Coffee brewed                     1 cup             2               0.7                               0            0
   Lunch                                                      340               58                              20            3
    Blue Menu Chicken Bangkok                1 pkg            230               32                2             19            3
    Juice, Orange                            1 cup            110               26                               2            0
   Dinner                                                     420               60                              27            8
    Blue Menu Chinese Sweet & Sour Chicken   1 pkg            350               60                2             22            2
    Marble cheese stick                      1                 70               0                                5            6
                                                                                                                               
  *Day 2*                                                   **1002**         **157**            **7**         **54**        **15**
   Breakfast                                                  249               41                               9            2
    Maple Brown Sugar Oatmeal                1 pkg            170               33                3              4            2
    Milk 2%                                  150 ml            77               7                                5            0
    Tea or Coffee brewed                     1 cup             2               0.7                               0            0
   Lunch                                                      333               57                              22            2
    Blue Menu Ginger Glazed Chicken          1 pkg            220               32                2             19            2
    Blue Menu Multigrain Pretzels            30 g             113               25                1              3           0.3
   Dinner                                                     420               59                              23            11
    Blue Menu Thai Sweet Chili Lemon Grass   1 pkg            350               59                1             18            5
    Chicken                                                                                                                    
    Marble cheese stick                      1 piece           70               0                                5            6
                                                                                                                               
  *Day 3*                                                   **1005**         **166**           **14**         **45**        **20**
   Breakfast                                                  246               45                               9            5
    Blue Menu Oatmeal Bagel                  1                160               30                5              7            2
    Blue Menu Old-Fashioned Peanut Butter    1 tsp             33               1                0.3             1            3
    Tea or Coffee brewed                     1 cup             2               0.7                               0            0
    Banana, fresh, medium                    1/2               53               13               1.5             1           0.2
   Lunch                                                      346               58                              14            6
    Blue Menu Roasted Vegetable Lasagna      1 pkg            240               33                3             12            6
    Banana, fresh, medium                    1/2               53               13               1.5             1           0.2
    Carrots, baby, fresh                     1 cup             53               12               2.5             1            0
   Dinner                                                     413               63                              22            9
    Blue Menu Indian Butter Chicken          1 pkg            370               52                2             21            9
    Orange, medium                           0.5               43               11                2              1            0

Abbreviations: pkg, package; tsp, teaspoon.
